CoChat

National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison

Open access

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

BACKGROUND AND OBJECTIVES: Globally, a number of countries have developed guidelines that describe the design and conduct of economic evaluations as part of health technology assessment (HTA) or pharmacoeconomic analysis for decision making. The current scoping review was undertaken with an objective to summarize the recommendations made on methods of economic evaluation by the national healthcare economic evaluation (HEE) guidelines. METHODOLOGY: A comprehensive search was undertaken in the website repositories of the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) and Guide to Economic Analysis and Research (GEAR), and websites of national HTA agencies and ministries of health of individual countries. All guidelines in the English language were included in this review. Data were extracted with respect to general and methodological characteristics, and a descriptive analysis of recommendations made across the countries was undertaken. RESULTS: Overall, our review included 31 national HEE guidelines, published between 1997 and August 2020. Nearly half (45%) of the guidelines targeted the evaluation of pharmaceuticals. The nature of the guidelines was either mandatory (31%), recommendatory (42%), or voluntary (16%). There was a substantial consensus among the guidelines on several key principles, including type of economic evaluation (cost-utility analysis), time horizon of the analysis (long enough), health outcome measure (quality-adjusted life-years) and use of sensitivity analyses. The recommendations on study perspective, comparator, discount rate and type of costs to be included (particularly the inclusion of indirect costs) varied widely. CONCLUSION: Despite similarity in the overall processes, variation in several recommendations given by various national HEE guidelines was observed. This is perhaps unsurprising given the differences in the health systems and financing mechanisms, capacity of local researchers, and data availability. This review offers important lessons and a starting point for countries that are planning to develop their own HEE guidelines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s41669-020-00250-7

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PRISMA flowchart of included national healthcare economic evaluation guidelines
Fig. 1 PRISMA flowchart of included national healthcare economic evaluation guidelinesCC BY-NC · PubMed Central
Fig. 2 Timeline of the publication of national healthcare economic evaluation guidelines
Fig. 2 Timeline of the publication of national healthcare economic evaluation guidelinesCC BY-NC · PubMed Central
Fig. 3 Discount rates recommended by national healthcare economic evaluation guidelines. SA South Africa
Fig. 3 Discount rates recommended by national healthcare economic evaluation guidelines. SA South AfricaCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 5

  1. Kobelt G Health economics: an introduction to economic evaluation 2013 3 London Office of Health Economics
  2. Austria Walter E Zehetmayr S Guidelines on health economic evaluation, consensus paper 2006 Vienna Institute for Pharmacoeconomic Research
  3. Cleemput I, Neyt M, Van de Sande S, Thiry N. Belgian guidelines for economic evaluations and budget impact analyses: second edition. Brussels: Belgian Health Care Knowledge Centre (KCE); 2012. KCE Reports 183C.
  4. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2017. https://www.cadth.ca/dv/guidelines-economic-evaluation-health-technologies-canada-4th-edition. Accessed 30 Dec 2020.
  5. National Institute for Health and Care Excellence [NICE]. Guide to the methods of technology appraisal 2013. London: NICE; 2013. https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 9 July 2020. 27905712

Cited by

See all 114

Metadata

Authors
Sharma, D., Aggarwal, A. K., Downey, L. E., & Prinja, S.
Affiliations
  • Post Graduate Institute of Medical Education and Research (IN)
  • Imperial College London (GB)
Corresponding author
Prinja, Shankar
Venue
PharmacoEconomics - Open
Published
2021-01-10
Volume
5
Issue
3
Pages
349-364
ISSN
  • 2509-4254 (ISSN-L)
  • 2509-4262
OpenAlex
W3118599774
Cited by
114
References
42
Citations by year
2026: 21 · 2025: 27 · 2024: 23 · 2023: 24 · 2022: 15 · 2021: 4
FWCI
3.23
Type
journal article
Language
en
Open access
Licence
Locations
  • PharmacoEconomics - Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc)
Funders
Indian Council of Medical Research
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Social Sciences › Sociology and Political Science › Delphi Technique in Research
Keywords
economic evaluation guidelines, health technology assessment, pharmacoeconomic evaluation, national guidelines, cross-national comparison, cost-utility analysis, quality-adjusted life years, discount rate, indirect costs, sensitivity analysis, drug evaluation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison. https://app.cochat.ai/papers/10.1007/s41669-020-00250-7
The paper
Sharma, D., Aggarwal, A. K., Downey, L. E., & Prinja, S. (2021). National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison. PharmacoEconomics - Open. https://doi.org/10.1007/s41669-020-00250-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.